SECdecoded Read filings, not jargon.

ELEVANCE HEALTH, INC. FY 2025 10-K, explained in plain English

ELV · 10-K for the period ending December 31, 2025, filed February 6, 2026 · Read the original on SEC.gov →

Key financials — as reported

Total revenue$199.1B
Gross margin89.4%
Operating income$7.2B
Net income$5.7B
Diluted EPS$25.21
Cash & equivalents$9.5B
Total assets$121.5B
Long-term debt$31.9B

Key takeaway

Elevance Health reported full-year 2025 revenue of $199.1B and net income of $5.66B, with benefits and expenses of $192.4B consuming the vast majority of revenue.

🔒 4 more takeaways in the full analysis

Beneath the surface

Cash and short-term investments ($9.49B cash + $25.88B current available-for-sale securities) total roughly $35.4B, which more than offsets the $31.9B long-term debt, suggesting a stronger net liquidity position than the headline debt figure alone implies.

🔒 3 more insights a headline reader would miss

This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for ELV.

Read the full analysis free Free account · 5 full analyses included · no card required